Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 21349192)

1.

A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.

Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-de-Figueiredo CE, Mion D, Bortolotto L, Consolim-Colombo F, Nobre F, Coelho EB, Vilela-Martin JF, Moreno H Jr, Cesarino EJ, Franco R, Brandão AA, de Sousa MR, Ribeiro AL, Jardim PC, Afiune Neto A, Scala LC, Mota M, Chaves H, Alves JG, Sobral Filho DC, Pereira e Silva R, Figueiredo Neto JA, Irigoyen MC, Castro I, Steffens AA, Schlatter R, de Mello RB, Mosele F, Ghizzoni F, Berwanger O.

Trials. 2011 Feb 24;12:53. doi: 10.1186/1745-6215-12-53.

2.

Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.

Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-de-Figueiredo CE, Mion D, Bortoloto L, Consolim-Colombo F, Nobre F, Coelho EB, Vilela-Martin JF, Moreno H Jr, Cesarino EJ, Franco R, Brandão AA, de Sousa MR, Ribeiro AL, Jardim PC, Neto AA, Scala LC, Mota M, Chaves H, Alves JG, Filho DC, Pereira e Silva R, Neto JA, Irigoyen MC, Castro I, Steffens AA, Schlatter R, de Mello RB, Mosele F, Ghizzoni F, Berwanger O.

Trials. 2011 Mar 5;12:65. doi: 10.1186/1745-6215-12-65.

3.

The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.

Cichelero FT, Martinez D, Fuchs SC, Gus M, Moreira LB, Fuchs FD.

Trials. 2014 Jan 2;15:1. doi: 10.1186/1745-6215-15-1.

5.

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.

Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.

Curr Med Res Opin. 2007 Feb;23(2):259-70.

PMID:
17288679
7.

What have we learned from the current trials?

Abbott KC, Bakris GL.

Med Clin North Am. 2004 Jan;88(1):189-207. Review.

PMID:
14871059
8.

The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Thomas GN, Chan P, Tomlinson B.

Drugs Aging. 2006;23(2):131-55. Review.

PMID:
16536636
9.

Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.

Shuster JE, Bleske BE, Dorsch MP.

Vasc Health Risk Manag. 2012;8:381-7. doi: 10.2147/VHRM.S22583. Epub 2012 Jun 13. Review.

11.

Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).

Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, Tikkanen I, Tilvis R, Pentikäinen PJ, Virolainen J, Kontula K.

Am J Hypertens. 2007 Mar;20(3):311-8.

PMID:
17324745
13.

The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.

Wang W, Ma L, Zhang Y, Deng Q, Liu M, Liu L.

J Hum Hypertens. 2011 Apr;25(4):271-7. doi: 10.1038/jhh.2010.45. Epub 2010 May 6.

14.

Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.

Meno H, Inou T, Tanaka M, Tsuchiya Y, Shiga Y, Kobayashi K, Nakamura Y, Ota T, Kubara I.

Arzneimittelforschung. 2012 Sep;62(9):414-9. doi: 10.1055/s-0032-1316376. Epub 2012 Jul 6.

PMID:
22773432
15.
16.

[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].

Zeller A, Battegay E.

Praxis (Bern 1994). 2005 Apr 13;94(15):581-94. Review. German.

PMID:
15884724
17.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
18.

Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study.

Toh R, Ishida T, Nishimura K, Nonaka H, Inoue Y, Kitagawa Y, Suematsu M, Miki T, Emoto N, Hirata K.

Hypertens Res. 2012 Nov;35(11):1080-6. doi: 10.1038/hr.2012.110. Epub 2012 Jul 12.

PMID:
22786569
19.

Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.

Hypertension. 2012 Aug;60(2):310-8. doi: 10.1161/HYPERTENSIONAHA.111.188284. Epub 2012 Jun 18.

20.

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2003 Sep;42(3):239-46. Epub 2003 Aug 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk